Floatz logo

Dantrolene

Wolfram Syndrome

Washington University School of MedicineSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Wolfram Syndrome cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Birmingham
Phase 2B
Depakine
Centre d'Etude des Cellules Souches
Phase 2CCC
Tirzepatide
Ospedale San Raffaele
Phase 2CCC
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 2CCC
Exenatide
Hadassah Medical Organization
N/AD

Same molecule, other indications

Dantrolene is also rated in:

optic atrophyDormant
CCC
Indicative ·
52 / 100
View asset →
atactic disorderDormant
CCC
Indicative ·
52 / 100
View asset →
diabetes mellitusDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →